Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 3/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6493159 | 0.79 | SIGMAR1 (0.47) | CCR5SIGMAR1DRD2 | |
| SCHEMBL6502613 | 0.76 | CYP19A1 (0.55) | HTR7CCR5CYP19A1SIGMAR1KDM4E | |
| SCHEMBL6076000 | 0.75 | HTR7 (0.68) | HTR7CCR5ADRA1DADRA1AADRA1B | |
| Hydrochloric Acid SCHEMBL6490470 | 0.74 | HTR7 (0.67) | HTR7CCR5ADRA1DADRA1AADRA1B | |
| SCHEMBL6499248 | 0.74 | DGAT1 (0.48) | HTR7CCR5ADRA1BSIGMAR1DRD2 | |
| SCHEMBL6503951 | 0.74 | DRD2 (0.40) | HTR7ADRA1DADRA1AADRA1BSIGMAR1 | |
| SCHEMBL8191001 | 0.72 | ADRA1D (0.51) | ADRA1DADRA1AADRA1BSIGMAR1DRD2 | |
| SCHEMBL7129359 | 0.71 | APP (0.42) | HTR7CCR5SIGMAR1DRD2 | |
| SCHEMBL8203575 | 0.69 | DRD2 (0.45) | SIGMAR1DRD2LMNA | |
| SCHEMBL2060926 | 0.69 | ACHE (0.47) | CYP19A1KDM4ELMNAPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6969724-B2 | Compounds | SMITHKLINE BEECHAM-SPA (GB) | 2005-11-29 | — | — | US | disclosed |
| US-20040024218-A1 | Novel compounds | SMITHKLINE BEECHAM SPA | 2004-02-05 | — | — | US | disclosed |
| EP-1129072-A2 | N-SUBSTITUTED AZACYCLES, THEIR PREPARATION AND THEIR USE AS ORL-1 RECEPTOR LIGANDS | Smithkline Beecham S.p.A. (IT) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000027815-A2 | N-SUBSTITUTED AZACYCLES, THEIR PREPARATION AND THEIR USE AS ORL-1 RECEPTOR LIGANDS | SMITHKLINE BEECHAM SPA (IT) | 2000-05-18 | — | — | WO | disclosed |
| US-6048877-A | Tetralone derivatives as antiarrhythmic agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024218-A1 | Novel compounds | OXER1, CLIC1, CCR1 | HTR7 1189/4885CCR5 206/4885ADRA1D 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.